[Indication of acemetacin in dermatological diseases (author's transl)].
In an open clinical study the anti-inflammatory effect and tolerability of the new non-steroidal drug, [1-(p-chlorobenzoyl)-5-methoxy-2-methylindol-3-acetoxy] acetic acid (acemetacin, TV 1322, Rantudil) were investigated on 12 female and 10 male patients aged between 20 and 67 years and suffering from the following syndromes: vasculitis, thrombophlebitis, erythematodes cutaneus, morbus Reiter, atopic dermatitis, non-specific prostatitis, periarteriitis nodosa, pemphigus vulgaris and dermatitis herpetiformis Duhring. Although the number of patients treated with the anti-inflammatory agent, acemetacin, was relatively small it was established that for in correct indications acemetacin had a good analgesic effect and reduced the consumption of cortison. Particularly interesting was the fact that no side effects occurred in any of the patients.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003348:Cortisone / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007210:Indoleacetic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D007213:Indomethacin / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D012871:Skin Diseases / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D007210:Indoleacetic Acids; C026784:acemetacin; D003348:Cortisone; D007213:Indomethacin
Indikation von Acemetacin bei dermatologischen Krankheitsbildern.